Enzon Pharmaceuticals Inc.

Enzon Pharmaceuticals Inc.

Enzon Pharmaceuticals Inc.

Overview
Date Founded

1983

Headquarters

20 Kingsbridge Road,Piscataway, NJ 08854

Type of Company

Public

Employees (Worldwide)

1

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services
Industrial Machinery & Manufacturing
Biotechnology

Company Description

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company was founded on September 17, 1981 and is headquartered in Cranford, NJ.

Contact Data
Trying to get in touch with decision makers at Enzon Pharmaceuticals Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer & Secretary

Vice President-Finance & Chief Financial Officer

Head of R&D

Director

Associate Director Quality Assurance

Associate Director Engineering

Network Administrator

Recruiting Consultant

Board of Directors

Managing Director at Icahn Enterprises LP

Former Associate Analyst at International Strategy & Investment Group LLC

Vice President of Investor Relations & Strategy at Calithera Biosciences, Inc.

Paths to Enzon Pharmaceuticals Inc.
Potential Connections via
Relationship Science
You
Enzon Pharmaceuticals Inc.
Owners & Shareholders
Details Hidden

Poplar Point Capital Management LLC is a private company headquartered in Burlingame, CA, that provides investment advice. The firm was founded in 2012. Jad Fakhry has been the CEO since the company founding.

Details Hidden

Harper Asset Management employs a fundamental, long-term value-oriented investment approach that focuses on investments in securities that are both financially safe and fundamentally undervalued. The firm evaluates the investment merits of individual securities. They avoid engaging in macroeconomic or other forecasting measures. Harper Asset Management seeks to maintain an appropriate margin of safety approach. The firm typically invests in companies with: low price relative to fundamental measures of value and their estimated long-term intrinsic value; reasonable downside protection; and measurable and predictable long-term earnings power. Harper Asset Management seeks to provide protection against permanent loss of capital while offering the potential for superior long-term investment performance. The firm's investment products include: Value Equity and Small-Cap Value Equity.Harper Asset Management's value equity composite is a blended record of all discretionary, fee-paying accounts which they manage in their primary, equity-only style. The firm's strategy is based on a bottom-up, fundamental, value-oriented investment approach, focusing on the margin of safety principle and targeting companies with low absolute valuations. Harper Asset Management may occasionally invest in the rare franchise equity, which is typically characterized by very high returns on invested capital. Their value equity product employs a multi-cap strategy, with a focus on the stocks of mid- to large-cap companies.Harper Asset Management offers their small-cap value investment product for institutional or wrap/sub-accounts. The product is managed based on the firm's bottom-up, value investment approach with a focus on margin of safety and low absolute valuations. Harper Asset Management's small-cap product includes investments in the stocks of micro-cap companies. The product invests in companies with a market-cap of $25 million-$2 billion.

Details Hidden

Poplar Point Capital Management LLC is a private company headquartered in Burlingame, CA, that provides investment advice. The firm was founded in 2012. Jad Fakhry has been the CEO since the company founding.

Recent Transactions
Details Hidden

ESSETIFIN SpA, Sigma-Tau Pharmaceuticals, Inc. purchase Enzon Pharmaceuticals, Inc. /Specialty Pharmaceutical Bus from Enzon Pharmaceuticals Inc.

Details Hidden

Enzon Pharmaceuticals Inc. issued Common Stock

Transaction Advisors
Investment Advisor

Advised onEnzon Pharmaceuticals Inc. purchases Elan Corp. Plc /Abelcet North American Operations from Elan Corp. Plc

Accountant

Advised onEnzon Pharmaceuticals Inc. purchases Elan Corp. Plc /Abelcet North American Operations from Elan Corp. Plc

Underwriter

Advised onEnzon Pharmaceuticals Inc. issued Common Stock

Legal Advisor

Advised onESSETIFIN SpA, Sigma-Tau Pharmaceuticals, Inc. purchase Enzon Pharmaceuticals, Inc. /Specialty Pharmaceutical Bus from Enzon Pharmaceuticals Inc.

Legal Advisor

Advised onESSETIFIN SpA, Sigma-Tau Pharmaceuticals, Inc. purchase Enzon Pharmaceuticals, Inc. /Specialty Pharmaceutical Bus from Enzon Pharmaceuticals Inc.

Advisors & Consultants
Consultant

Partner & Research Director at Barington Capital Group LP

Advisor

Chief Executive Officer & Secretary at Enzon Pharmaceuticals Inc.

Consultant

President at Leaders By Design

Clients

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Key Stats and Financials As of 2018
Market Capitalization
$10.2M
Total Enterprise Value
$4.64M
Earnings Per Share
$0.13
Revenue
$6.92M
EBITDAMargin
84.63%
Enterprise Value Sales
0.67x
Enterprise Value EBITDAOperating
0.79x
TEVNet Income
0.79x
Debt TEV
0x
EBITDA
$5.86M
Total Debt
$0
Total Equity
$15M
Net Profit
$5.85M
Three Year Compounded Annual Growth Rate Of Revenue
-26.55%
Five Year Compounded Annual Growth Rate Of Revenue
-27.48%
Non-Profit Donations & Grants
Political Donations
$2,200
2001
Competitors
AbbVie, Inc. Pharmaceuticals - North Chicago , IL

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on 2013 and is headquartered in North Chicago, IL.

Bristol-Myers Squibb Company Pharmaceuticals - New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Bayer AG Pharmaceuticals - Leverkusen, NW

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and acts as a socially and ethically responsible corporate citizen. In fiscal year 2012, Bayer employed 110,500 people and had sales of €39.8 billion. Capital expenditures amounted to €2 billion, R&D expenses to €3 billion.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Enzon Pharmaceuticals Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Enzon Pharmaceuticals Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Enzon Pharmaceuticals Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/enzon-pharmaceuticals-inc-5057
  • https://relationshipscience.com/organization/enzon-pharmaceuticals-inc-5057